Pulmatrix Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Pulmatrix.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.9%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Aug 02

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Pulmatrix non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:PULM - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2024	10	-10	-12	-11	N/A
6/30/2024	11	-11	-14	-13	N/A
3/31/2024	12	-9	-15	-14	N/A
12/31/2023	7	-14	-17	-16	N/A
9/30/2023	7	-16	-19	-19	N/A
6/30/2023	7	-18	-19	-18	N/A
3/31/2023	6	-18	-18	-18	N/A
12/31/2022	6	-19	-19	-19	N/A
9/30/2022	5	-22	-19	-19	N/A
6/30/2022	4	-25	-19	-18	N/A
3/31/2022	5	-24	-21	-20	N/A
12/31/2021	5	-23	-20	-20	N/A
9/30/2021	7	-19	-18	-18	N/A
6/30/2021	10	-21	-21	-20	N/A
3/31/2021	11	-19	-19	-19	N/A
12/31/2020	13	-19	-13	-12	N/A
9/30/2020	12	-20	-14	-14	N/A
6/30/2020	9	-13	-13	-13	N/A
3/31/2020	11	-20	7	7	N/A
12/31/2019	8	-21	3	3	N/A
9/30/2019	6	-21	3	3	N/A
6/30/2019	5	-22	3	3	N/A
3/31/2019	N/A	-20	-17	-17	N/A
12/31/2018	0	-21	-17	-17	N/A
9/30/2018	0	-21	-16	-16	N/A
6/30/2018	0	-20	N/A	-16	N/A
3/31/2018	0	-20	N/A	-15	N/A
12/31/2017	0	-18	N/A	-14	N/A
9/30/2017	0	-23	N/A	-14	N/A
6/30/2017	0	-22	N/A	-12	N/A
3/31/2017	0	-26	N/A	-12	N/A
12/31/2016	1	-28	N/A	-13	N/A
9/30/2016	1	-23	N/A	-14	N/A
6/30/2016	2	-24	N/A	-14	N/A
3/31/2016	1	-30	N/A	-14	N/A
12/31/2015	1	-26	N/A	-12	N/A
9/30/2015	1	-6	N/A	-11	N/A
6/30/2015	1	-13	N/A	-10	N/A
3/31/2015	0	-5	N/A	-9	N/A
12/31/2014	0	-6	N/A	-9	N/A
12/31/2013	1	-13	N/A	-10	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista PULM è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di PULM cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di PULM cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di PULM cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di PULM cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PULM è previsto essere elevato tra 3 anni

Pulmatrix Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates increase by 16%

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

Price target decreased to US$10.00

No longer forecast to breakeven

Price target increased to US$200

No longer forecast to breakeven

Recent updates

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

New major risk - Share price stability

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Second quarter 2024 earnings released: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita